Budesonide-MMX for Mild-to-Moderate Ulcerative Colitis
Budesonide-MMX is well tolerated and efficacious in mild-to-moderate UC, with available data supporting the hypothesis that low bioavailability and targeted delivery of budesonide limit side effects. While 5-ASA agents remain the first-line therapy for inducing and maintaining remission of mild or moderately active UC, budesonide-MMX should be considered as an alternative to systemic steroids as the next step in mild-to-moderate UC refractory to 5-ASA.
Conclusions
Budesonide-MMX is well tolerated and efficacious in mild-to-moderate UC, with available data supporting the hypothesis that low bioavailability and targeted delivery of budesonide limit side effects. While 5-ASA agents remain the first-line therapy for inducing and maintaining remission of mild or moderately active UC, budesonide-MMX should be considered as an alternative to systemic steroids as the next step in mild-to-moderate UC refractory to 5-ASA.
SHARE
